Federal Register / Vol. 87, No. 106 / Thursday, June 2, 2022 / Notices 33497 

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

HHS, with the HHS’ NLCP contractor continuing to 

have an active role in the performance testing and 

laboratory inspection processes. Other Canadian 

laboratories wishing to be considered for the NLCP 

may apply directly to the NLCP contractor just as 

U.S. laboratories do. 

drug and specimen validity tests on oral 

fluid specimens: 

At this time, there are no laboratories 

certified to conduct drug and specimen 

validity tests on oral fluid specimens. 

HHS-Certified Instrumented Initial 

Testing Facilities Approved To Conduct 

Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified IITFs meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

Dynacare, 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190 (Formerly: GammaDynacare Medical Laboratories) 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified laboratories meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

Cordant Health Solutions, 2617 East L 

Street, Tacoma, WA 98421, 800–442– 

0438 (Formerly: STERLING Reference 

Laboratories) 

Desert Tox, LLC, 5425 E Bell Rd, Suite 

125, Scottsdale, AZ 85254, 602–457– 

5411/623–748–5045 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

Dynacare*, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630 (Formerly: GammaDynacare Medical Laboratories) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609 

Laboratory Corporation of America 

Holdings, 7207 N Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339 (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center) 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Legacy Laboratory Services Toxicology, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295 

MedTox Laboratories, Inc., 402 W 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. Testing for Veterans Affairs 

(VA) Employees Only 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942 (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory) 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

U.S. Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085, Testing for 

Department of Defense (DoD) 

Employees Only 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on January 23, 2017 (82 FR 

7920). After receiving DOT certification, 

the laboratory will be included in the 

monthly list of HHS-certified 

laboratories and participate in the NLCP 

certification maintenance program. 

Anastasia Marie Donovan, 

Public Health Advisor, Division of Workplace 

Programs. 

[FR Doc. 2022–11821 Filed 6–1–22; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2020–0016] 

Meetings To Implement Pandemic 

Response Voluntary Agreement Under 

Section 708 of the Defense Production 

Act 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Announcement of meetings. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA) is holding 

quarterly status meetings under each of 

the six Plans of Action, in the 

corresponding order listed below, to 

implement the Voluntary Agreement for 

the Manufacture and Distribution of 

Critical Healthcare Resources Necessary 

to Respond to a Pandemic. 

• Plan of Action to Establish a 

National Strategy for the Manufacture, 

Allocation, and Distribution of Medical 

Gases to Respond to COVID–19. 

• Plan of Action to Establish a 

National Strategy for the Manufacture, 

Allocation, and Distribution of Personal 

Protective Equipment (PPE) to Respond 

to COVID–19. 

• Plan of Action to Establish a 

National Strategy for the Manufacture, 

Allocation, and Distribution of 

Diagnostic Test Kits and other Testing 

Components to Respond to COVID–19. 

• Plan of Action to Establish a 

National Strategy for the Manufacture, 


jspears on DSK121TN23PROD with NOTICES1
33498 Federal Register / Vol. 87, No. 106 / Thursday, June 2, 2022 / Notices 

1 50 U.S.C. 4558(c)(1). 

2 85 FR 18403 (Apr. 1, 2020). 

3 DHS Delegation 09052, Rev. 00.1 (Apr. 1, 2020); 

DHS Delegation Number 09052 Rev. 00 (Jan. 3, 

2017). 

4 85 FR 50035 (Aug. 17, 2020). The Attorney 

General, in consultation with the Chairman of the 

Federal Trade Commission, made the required 

finding that the purpose of the voluntary agreement 

may not reasonably be achieved through an 

agreement having less anticompetitive effects or 

without any voluntary agreement and published the 

finding in the Federal Register on the same day. 85 

FR 50049 (Aug. 17, 2020). 

5See 85 FR 78869 (Dec. 7, 2020). See also 85 FR 

79020 (Dec. 8, 2020). 

6See 86 FR 27894 (May 24, 2021). See also 86 FR 

28851 (May 28, 2021). 

7See 86 FR 57444 (Oct. 15, 2021). See also 87 FR 

6880 (Feb. 7, 2022). 

8See 50 U.S.C. 4558(h)(7). 

9 ‘‘[T]he individual designated by the President in 

subsection (c)(2) [of section 708 of the DPA] to 

administer the voluntary agreement, or plan of 

action.’’ 50 U.S.C. 4558(h)(7). 

Allocation, and Distribution of Medical 

Devices to Respond to COVID–19. 

• Plan of Action to Establish a 

National Strategy for the Coordination 

of National Multimodal Healthcare 

Supply Chains to Respond to COVID– 

19. 

• Plan of Action to Establish a 

National Strategy for the Manufacture, 

Allocation, and Distribution of Drug 

Products, Drug Substances, and 

Associated Medical Devices to Respond 

to COVID–19. 

DATES: 

• Thursday, June 2, 2022, from 2:00 

p.m. to 3:00 p.m. Eastern Time (ET). 

• Thursday, June 16, 2022, from 1:30 

p.m. to 2:30 p.m. ET. 

• Thursday, June 23, 2022, from 1:30 

p.m. to 2:30 p.m. ET. 

• Thursday, June 30, 2022, from 1:30 

p.m. to 2:30 p.m. ET. 

• Thursday, July 21, 2022, from 1:30 

p.m. to 2:30 p.m. ET. 

• Tuesday, July 26, 2022, from 1:30 

p.m. to 2:30 p.m. ET. 

FOR FURTHER INFORMATION CONTACT: 

Mary Anne Lyle, Office of Business, 

Industry, and Infrastructure Integration, 

via email at OB3I@fema.dhs.gov or via 

phone at (202) 212–1666. 

SUPPLEMENTARY INFORMATION: Notice of 

these meetings is provided as required 

by section 708(h)(8) of the Defense 

Production Act (DPA), 50 U.S.C. 

4558(h)(8), and consistent with 44 CFR 

part 332. 

The DPA authorizes the making of 

‘‘voluntary agreements and plans of 

action’’ with representatives of industry, 

business, and other interests to help 

provide for the national defense.1 The 

President’s authority to facilitate 

voluntary agreements with respect to 

responding to the spread of COVID–19 

within the United States was delegated 

to the Secretary of Homeland Security 

in Executive Order 13911.2 The 

Secretary of Homeland Security further 

delegated this authority to the FEMA 

Administrator.3

On August 17, 2020, after the 

appropriate consultations with the 

Attorney General and the Chairman of 

the Federal Trade Commission, FEMA 

completed and published in the Federal 

Register a ‘‘Voluntary Agreement, 

Manufacture and Distribution of Critical 

Healthcare Resources Necessary to 

Respond to a Pandemic’’ (Voluntary 

Agreement).4 Unless terminated earlier, 

the Voluntary Agreement is effective 

until August 17, 2025, and may be 

extended subject to additional approval 

by the Attorney General after 

consultation with the Chairman of the 

Federal Trade Commission. The 

Agreement may be used to prepare for 

or respond to any pandemic, including 

COVID–19, during that time. 

On December 7, 2020, the first plan of 

action under the Voluntary 

Agreement—the Plan of Action to 

Establish a National Strategy for the 

Manufacture, Allocation, and 

Distribution of Personal Protective 

Equipment (PPE) to Respond to COVID– 

19 (PPE Plan of Action)—was finalized.5

The PPE Plan of Action established 

several sub-committees under the 

Voluntary Agreement, focusing on 

different aspects of the PPE Plan of 

Action. 

On May 24, 2021, four additional 

plans of action under the Voluntary 

Agreement—the Plan of Action to 

Establish a National Strategy for the 

Manufacture, Allocation, and 

Distribution of Diagnostic Test Kits and 

other Testing Components to respond to 

COVID–19, the Plan of Action to 

Establish a National Strategy for the 

Manufacture, Allocation, and 

Distribution of Drug Products, Drug 

Substances, and Associated Medical 

Devices to respond to COVID–19, the 

Plan of Action to Establish a National 

Strategy for the Manufacture, 

Allocation, and Distribution of Medical 

Devices to respond to COVID–19, and 

the Plan of Action to Establish a 

National Strategy for the Manufacture, 

Allocation, and Distribution of Medical 

Gases to respond to COVID–19—were 

finalized.6 These plans of action 

established several sub-committees 

under the Voluntary Agreement, 

focusing on different aspects of each 

plan of action. 

On October 15, 2021, the sixth plan of 

action under the Voluntary 

Agreement—the Plan of Action to 

Establish a National Strategy for the 

Coordination of National Multimodal 

Healthcare Supply Chains to Respond to 

COVID–19—was finalized.7 This plan of 

action established several subcommittees under the Voluntary 

Agreement, focusing on different 

transportation categories. 

The meetings are chaired by the 

FEMA Administrator’s delegates from 

the Office of Response and Recovery 

(ORR) and Office of Policy and Program 

Analysis (OPPA), attended by the 

Attorney General’s delegates from the 

U.S. Department of Justice, and attended 

by the Chairman of the Federal Trade 

Commission’s delegates. In 

implementing the Voluntary Agreement, 

FEMA adheres to all procedural 

requirements of 50 U.S.C. 4558 and 44 

CFR part 332. 

Meeting Objectives: The objectives of 

the meetings are as follows: 

1. Convene the Requirements SubCommittees under each of the six Plans 

of Action to establish priorities related 

to the COVID–19 response under the 

Voluntary Agreement. 

2. Gather Requirements SubCommittee Participants and Attendees 

to ask targeted questions for situational 

awareness. 

3. Identify pandemic-related 

information gaps and areas that merit 

sharing by holding these regular 

quarterly meetings of the Requirements 

Sub-Committees with key stakeholders. 

4. Identify potential Objectives and 

Actions that should be completed under 

the Requirements Sub-Committees. 

Meetings Closed to the Public: By 

default, the DPA requires meetings held 

to implement a voluntary agreement or 

plan of action be open to the public.8

However, attendance may be limited if 

the Sponsor 9 of the Voluntary 

Agreement finds that the matter to be 

discussed at a meeting falls within the 

purview of matters described in 5 U.S.C. 

552b(c), such as trade secrets and 

commercial or financial information. 

The Sponsor of the Voluntary 

Agreement, the FEMA Administrator, 

found that these meetings to implement 

the Voluntary Agreement involve 

matters which fall within the purview of 

matters described in 5 U.S.C. 552b(c) 

and the meetings are therefore closed to 

the public. 

Specifically, these meetings may 

require participants to disclose trade 

secrets or commercial or financial 

information that is privileged or 

confidential. Disclosure of such 

information allows for meetings to be 

closed to the public pursuant to 5 U.S.C. 

552b(c)(4). 

The success of the Voluntary 

Agreement depends wholly on the 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 106 / Thursday, June 2, 2022 / Notices 33499 

willing participation of the private 

sector participants. Failure to close 

these meetings to the public could 

reduce active participation by the 

signatories due to a perceived risk that 

sensitive company information could be 

released to the public. A public 

disclosure of a private sector 

participant’s information executed 

prematurely could reduce trust and 

support for the Voluntary Agreement. 

A resulting loss of support by the 

participants for the Voluntary 

Agreement would significantly hinder 

the implementation of the Agency’s 

objectives. Thus, these meeting closures 

are permitted pursuant to 5 U.S.C. 

552b(c)(9)(B). 

Deanne Criswell, 

Administrator, Federal Emergency 

Management Agency. 

[FR Doc. 2022–11842 Filed 6–1–22; 8:45 am] 

BILLING CODE 9111–19–P 

DEPARTMENT OF HOMELAND 

SECURITY 

[Docket Number DHS–2022–0031] 

Agency Information Collection 

Activities: IMMVI Veterans Portal, 

Webform 1601–0032 

AGENCY: Department of Homeland 

Security (DHS). 

ACTION: 60-Day notice and request for 

comments. 

SUMMARY: The Department of Homeland 

Security, will submit the following 

Information Collection Request (ICR) to 

the Office of Management and Budget 

(OMB) for review and clearance in 

accordance with the Paperwork 

Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted until August 1, 2022. 

This process is conducted in accordance 

with 5 CFR 1320.1. 

ADDRESSES: You may submit comments, 

identified by docket number Docket # 

DHS–2022–0031, at: 

Æ Federal eRulemaking Portal: http:// 

www.regulations.gov. Please follow the 

instructions for submitting comments. 

Instructions: All submissions received 

must include the agency name and 

docket number Docket # DHS–2022– 

0031. All comments received will be 

posted without change to http://

www.regulations.gov, including any 

personal information provided. 

Docket: For access to the docket to 

read background documents or 

comments received, go to http://

www.regulations.gov. 

SUPPLEMENTARY INFORMATION: On 

February 2, 2021 President Biden signed 

Executive Order 14012 Restoring Faith 

in Our Legal Immigration Systems and 

Strengthening Integration and Inclusion 

Efforts for New Americans. The role of 

the White House Domestic Policy 

Council (DPC) is to convene executive 

departments and agencies (agencies) to 

coordinate the formulation and 

implementation of the Administration’s 

domestic policy objectives. Consistent 

with that role, the DPC shall coordinate 

the Federal Government’s efforts to 

welcome and support immigrants, 

including refugees, and to catalyze State 

and local integration and inclusion 

efforts. In furtherance of these goals, the 

DPC shall convene a Task Force on New 

Americans, which shall include 

members of agencies that implement 

policies that impact immigrant 

communities. 

In response to E.O. 14012, on July 2, 

2021, the Secretaries of Homeland 

Security and Veterans Affairs 

announced a new joint initiative, the 

Immigrant Military Members and 

Veterans Initiative (IMMVI), to support 

our Nation’s noncitizen service 

members, veterans, and their immediate 

family members and directed their 

departments to identify and prioritize 

the return of military service members, 

veterans, and their immediate family 

members who were unjustly removed 

from the United States and ensure that 

they receive the benefits to which they 

may be entitled. 

The information to be collected for 

self-disclosure would include: 

A-Number, USCIS Receipt Numbers (if 

any), Name, Date of Birth, Country of 

Residence, Email, Phone Number, 

Branch and Dates of Military Service, 

Address, reason for requesting 

assistance, and Name and Contact 

Information of Representative, if 

applicable. 

To carry out the goals of IMMVI, DHS 

is proposing this new data collection to 

offer noncitizen current and former 

military members and their families an 

opportunity to seek assistance from 

DHS. The purpose of this information 

collection is to achieve efficiencies in 

making contact with individuals, better 

understand their needs, and track and 

report the number and types of inquiries 

received. This information will assist 

DHS in improving access to immigration 

services and VA health benefits. DHS 

plans to collect relevant information to 

provide assistance at the point the 

individual submits this information on 

the new website for benefits and 

immigration assistance. The information 

collected through this public facing 

webform will be voluntarily provided 

by the users. 

A new webform hosted on dhs.gov 

will be established to allow for 

individuals to submit the necessary 

information to make contact with the 

government to seek assistance. 

Additionally, the government provides 

an email address for those who are not 

able to access the webform. The 

government will then reach out to the 

individual to provide them with the 

necessary information needed to request 

immigration or VA benefits. The 

progress of the inquiries will be tracked 

in a DHS case management system. 

The non-citizen current or former 

servicemember or their family member 

will submit their information through a 

webform on dhs.gov. The information 

will be transmitted to government 

systems and shared with the 

cooperating DHS components and 

agencies assisting the former military 

members and their families. All 

information related to the individual’s 

request and action taken by the 

government will be noted in the case 

management system for tracking and 

appropropriate follow through and 

action. 

If the collection of information 

impacts small businesses or other small 

entities (Item 5 of OMB Form 83–I), 

describe any methods used to minimize 

burden. 

All information received through the 

DHS website will be reviewed by 

trained DHS federal staff assigned to 

IMMVI and stored in a DHS case 

management system. No information 

will be shared with other agencies 

without the appropriate privacy releases 

from the individuals accessing the 

portal. All information received through 

the portal and any actions taken in 

response to the information collected 

will be stored in a DHS case 

management system. 

This is a new information collection 

request. 

The Office of Management and Budget 

is particularly interested in comments 

which: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 


jspears on DSK121TN23PROD with NOTICES1